We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00168129
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : December 9, 2011
Information provided by:

Study Description
Brief Summary:
To assess the safety and efficacy of a single fraction of radiotherapy using helical tomotherapy to treat bone metastases.

Condition or disease Intervention/treatment Phase
Bone Neoplasms Procedure: Helical tomotherapy Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases
Study Start Date : June 2001
Estimated Study Completion Date : July 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bone Cancer
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. To deliver a single fraction of radiotherapy safely to patients with bone metastases using helical tomotherapy

Secondary Outcome Measures :
  1. To assess and quantify the acute toxicity of patients with bone metastases treated with helical tomotherapy.
  2. To measure invivo dosimetry and compare delivered doses to computer-reconstructed dose distribution.
  3. To determine the maximum tolerated does of palliative radiation give with helical tomotherapy in a single fraction.
  4. To assess the efficacy (pain control) of radiotherapy given with helical tomotherapy.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • painful metastatic bone disease from any malignancy

Exclusion Criteria:

  • previous RT to same area
  • contraindications to RT
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168129

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada
Sponsors and Collaborators
Alberta Health Services
Principal Investigator: Rufus Scrimger, MD AHS Cancer Control Alberta
More Information

ClinicalTrials.gov Identifier: NCT00168129     History of Changes
Other Study ID Numbers: NA-15-0007
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: December 9, 2011
Last Verified: December 2011

Keywords provided by AHS Cancer Control Alberta:
bone metastases
intensity modulated

Additional relevant MeSH terms:
Neoplasm Metastasis
Bone Neoplasms
Neoplastic Processes
Pathologic Processes
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases